- $1.38bn
- $1.13bn
- $4.09m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.23 | ||
| Price to Tang. Book | 6.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 338.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -236.65% | ||
| Return on Equity | -390.36% | ||
| Operating Margin | -15582.27% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 20.38 | 0.23 | 0.31 | 0.31 | 4.09 | 0.17 | 0.14 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- December 30th, 2025
- Public Since
- June 18th, 2021
- No. of Shareholders
- 344
- No. of Employees
- 99
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 364,745,985
- Address
- NEW YORK, 10119
- Web
- https://www.ataibeckley.com/
- Phone
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ATAI
Q1 2026 Atai Beckley NV Earnings Release
Atai Beckley NV Annual Shareholders Meeting
Q2 2026 AtaiBeckley Inc Earnings Release
Similar to ATAI
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
What is the AtaiBeckley share price?
As of Today at 19:24 UTC, shares in AtaiBeckley are trading at $3.79. This share price information is delayed by 15 minutes.
How has the AtaiBeckley share price performed this year?
Shares in AtaiBeckley last closed at $3.79 and the price had moved by +156.08% over the past 365 days. In terms of relative price strength the AtaiBeckley share price has outperformed the S&P500 Index by +97.39% over the past year.
What are the analyst and broker recommendations for AtaiBeckley?
The overall consensus recommendation for AtaiBeckley is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the AtaiBeckley dividend yield?
AtaiBeckley does not currently pay a dividend.
Does AtaiBeckley pay a dividend?
AtaiBeckley does not currently pay a dividend.
When does AtaiBeckley next pay dividends?
AtaiBeckley does not currently pay a dividend.
How do I buy AtaiBeckley shares?
To buy shares in AtaiBeckley you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AtaiBeckley?
As of the previous close price of $3.79, shares in AtaiBeckley had a market capitalisation of $1.38bn.
Where are AtaiBeckley shares listed?
Here are the trading details for AtaiBeckley:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ATAI
What kind of share is AtaiBeckley?
Based on an overall assessment of its quality, value and momentum AtaiBeckley is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AtaiBeckley share price forecast for 2026?
The analyst consensus target price for shares in AtaiBeckley is $13.33. That is 251.72% above the last closing price of $3.79.
Analysts covering AtaiBeckley currently have a consensus Earnings Per Share (EPS) forecast of -$0.46 for the next financial year.
Find out moreWhat is the trend in the AtaiBeckley share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AtaiBeckley. Over the past six months, its share price has underperformed the S&P500 Index by -25.8%.
As of the last closing price of $3.79, shares in AtaiBeckley were trading -7.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AtaiBeckley PE Ratio?
The AtaiBeckley PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AtaiBeckley?
We do not have data on AtaiBeckley's directors